WEEKEND SPECIAL (NASDAQ:ANAC)

ANALYST RATING: STRONG BUY

Anacor Pharmaceuticals Inc (NASDAQ: ANAC)

•  
•  
•  
• 

5.80  +0.17 +3.02%

MORE ON ANAC

• SUMMARY
• Quote
• Options
• Historical Prices
• CHARTS
• Interactive Chart
• NEWS
• Headlines
• Key Developments
• FUNDAMENTALS
• Financial Highlights
• Profile
• Key Ratios
• 10-Year Summary
• Earnings
• SEC Filings
• RATINGS/ANALYSIS
• StockScouter Report
• Analyst Ratings
• INSIDER ACTION
• Insider Trades
• Ownership
• FINANCIALS
• Income Statement
• Balance Sheet
• Cash Flow
•  

COMPANY ADDRESS

Anacor Pharmaceuticals Inc
1020 East Meadow Circle
PALO ALTO, CA 94303-4230
US - Map
Phone: 650-5437500
Fax: 650-5437660
Website 

COMPANY INFORMATION

Exchange:	NASDAQ
Stock:	Anacor Pharmaceuticals Inc
Industry:	Biotechnology
Employees:	80

DESCRIPTION

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company has five product candidates in clinical development. Its three product candidates include two topically administered dermatologic compounds: AN2690, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria GSK2251052 (GSK '052). The Company is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. In August 2010, it entered into a research agreement with Eli Lilly and Company (Lilly).